ARS Pharma Q2 2026: neffy revenue $26.2M, net loss $62.3M, cuts 2H expenses

ARS Pharmaceuticals, Inc.

Q2 neffy net product revenue $26.2M; total revenue $33.7M incl. $7.4M supply revenue.
Net loss $62.3M ($0.63/share); cash $143.8M at June 30, 2026.
2H 2026 SG&A+R&D guided $114-126M (cash-based $100-110M); >40% cut in cash SG&A vs 1H.
Meg Smith appointed CCO effective Aug 17, 2026; field sales expansion complete.
Phase 2b CSU trial interim data expected Q1 2027; no approved on-demand CSU flare treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.